Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303)

Cancer

Volumn 118, Issue 2, 2012, Pages 571-578

  Roberts, Andrew S ^a   Campa, Michael J ^a   Gottlin, Elizabeth B ^a   Jiang, Chen ^a   Owzar, Kouros ^a   Kindler, Hedy L ^b   Venook, Alan P ^c   Goldberg, Richard M ^d   O'Reilly, Eileen M ^e   Patz Jr , Edward F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Alpha 1 antichymotrypsin; Bevacizumab; Biological markers; Pancreatic neoplasms; Prognosis

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; BEVACIZUMAB; COMPLEMENT FACTOR H; GEMCITABINE; GLYCOPROTEIN; HISTIDINE RICH GLYCOPROTEIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PEPTIDE MAPPING; PHASE 3 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; SURVIVAL TIME; TANDEM MASS SPECTROMETRY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTICHYMOTRYPSIN; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855496672     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26270     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362: 1605-1617.
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
4. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
6. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
7. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
8. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040. (Pubitemid 46657405)
9. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
10. Akritas MG, Siebert J. Testing for partial association using Kendall's tau with censored astronomical data. MNRAS. 1996;278:919.
11. Koomen JM, Shih LN, Coombes KR, et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res. 2005;11:1110-1118. (Pubitemid 40175760)
12. Ogoshi K, Tajima T, Mitomi T, Tsuda M, Yamamura M. Acute-phase plasma proteins in gastric cancer: association with metastatic potential and prognosis. Tumour Biol. 1996; 17:281-289. (Pubitemid 26276121)
13. Higashiyama M, Doi O, Yokouchi H, Kodama K, Nakamori S, Tateishi R. Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression. Cancer. 1995;76:1368-1376.
14. Zou Z, Anisowicz A, Hendrix MJ, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science. 1994;263:526-529. (Pubitemid 24082753)
15. Kataoka H, Itoh H, Koono M. Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration. Pathol Int. 2002;52:89-102. (Pubitemid 34298095)
16. Montel V, Pestonjamasp K, Mose E, Tarin D. Tumor-host interactions contribute to the elevated expression level of alpha1-antichymotrypsin in metastatic breast tumor xenografts. Differentiation. 2005;73:88-98. (Pubitemid 41583381)
17. Juarez JC, Guan X, Shipulina NV, et al. Histidine-prolinerich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain. Cancer Res. 2002;62:5344-5350. (Pubitemid 35024611)
18. Chelius D, Bondarenko PV. Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. J Proteome Res. 2002;1:317-323. (Pubitemid 36395872)
19. Annesley TM. Ion suppression in mass spectrometry. Clin Chem. 2003;49:1041-1044. (Pubitemid 36751088)
20. Qian WJ, Jacobs JM, Liu T, Camp DG II, Smith RD. Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications. Mol Cell Proteomics. 2006;5:1727-1744. (Pubitemid 44696109)
21. Brand J, Haslberger T, Zolg W, Pestlin G, Palme S. Depletion efficiency and recovery of trace markers from a multiparameter immunodepletion column. Proteomics. 2006;6: 3236-3242. (Pubitemid 43886142)